Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
1.025
+0.036 (3.66%)
At close: Aug 26, 2025, 4:00 PM
1.030
+0.005 (0.49%)
After-hours: Aug 26, 2025, 4:10 PM EDT
Oncolytics Biotech Stock Forecast
Stock Price Forecast
The 4 analysts that cover Oncolytics Biotech stock have a consensus rating of "Strong Buy" and an average price target of $5.00, which forecasts a 387.80% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $7.00.
Price Target: $5.00 (+387.80%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Oncolytics Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +582.93% | Aug 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +387.80% | May 21, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $5 → $3 | Strong Buy | Maintains | $5 → $3 | +192.68% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +387.80% | Mar 10, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.52M
EPS This Year
-0.40
from -0.41
EPS Next Year
-0.42
from -0.40
Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 6.3M | |||
| Avg | n/a | 1.5M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.36 | -0.38 | |||
| Avg | -0.40 | -0.42 | |||
| Low | -0.46 | -0.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.